Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
World Health Organization. Obesity and overweight. (2024).Non-Communicable Disease Risk Factor Collaboration. Worldwide trends in underweight and obesity from 1990 to...